$1.39 Billion is the total value of Sofinnova Investments, Inc.'s 135 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 71.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NXTC | Buy | Nextcure, Inc | $150,506,000 | +93.5% | 2,671,856 | +5.9% | 10.85% | +54.2% |
| KRTX | Buy | Karuna Therapeutics, Inc. | $142,061,000 | +403.4% | 1,885,602 | +9.0% | 10.24% | +301.3% |
| YMAB | Buy | Y-mAbs Therapeutics, Inc | $68,571,000 | +25.0% | 2,194,278 | +4.3% | 4.94% | -0.3% |
| GRTX | New | Galera Therapeutics, Inc | $40,582,000 | – | 3,083,712 | +100.0% | 2.92% | – |
| BMRN | Buy | Biomarin Pharmaceutical Inc | $37,360,000 | +552.9% | 441,872 | +420.5% | 2.69% | +420.9% |
| VRTX | Buy | Vertex Pharmaceuticals Inc | $30,470,000 | +47.8% | 139,164 | +14.4% | 2.20% | +17.8% |
| PTCT | Buy | PTC Therapeutics Inc | $24,836,000 | +155.6% | 517,092 | +80.0% | 1.79% | +103.9% |
| MRK | New | Merck & Co Inc | $21,901,000 | – | 240,806 | +100.0% | 1.58% | – |
| BIIB | New | Biogen Inc | $18,904,000 | – | 63,711 | +100.0% | 1.36% | – |
| REGN | New | Regeneron Pharmaceuticals Inc | $18,806,000 | – | 50,086 | +100.0% | 1.36% | – |
| CCXI | New | ChemoCentryx Inc | $14,907,000 | – | 376,944 | +100.0% | 1.07% | – |
| MYOK | Buy | MyoKardia Inc | $14,276,000 | +140.3% | 195,871 | +71.9% | 1.03% | +91.6% |
| MRTX | Buy | Mirati Therapeutics Inc | $13,966,000 | +482.2% | 108,383 | +251.9% | 1.01% | +364.1% |
| MGNX | Buy | MacroGenics Inc | $12,772,000 | +72.1% | 1,173,882 | +101.9% | 0.92% | +37.3% |
| FATE | Buy | Fate Therapeutics Inc | $12,430,000 | +109.8% | 635,143 | +66.4% | 0.90% | +67.2% |
| New | Alnylam Pharmaceuticals Inccall | $11,517,000 | – | 100,000 | +100.0% | 0.83% | – | |
| New | Medicines Coput | $9,343,000 | – | 110,000 | +100.0% | 0.67% | – | |
| CALA | Buy | Calithera Biosciences Inc | $8,331,000 | +179.4% | 1,458,821 | +51.2% | 0.60% | +122.2% |
| New | Alexion Pharmaceuticals Inccall | $8,112,000 | – | 75,000 | +100.0% | 0.58% | – | |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $7,421,000 | +401.1% | 2,151,164 | +316.3% | 0.54% | +299.3% |
| OTIC | Buy | Otonomy Inc | $5,804,000 | +68.9% | 1,515,629 | +5.4% | 0.42% | +34.4% |
| SGEN | New | Seattle Genetics Inc | $5,712,000 | – | 50,000 | +100.0% | 0.41% | – |
| KALA | Buy | Kala Pharmaceuticals Inc | $2,453,000 | +34.9% | 664,641 | +39.0% | 0.18% | +7.9% |
| RYTM | New | Rhythm Pharmaceuticals Inc | $489,000 | – | 21,319 | +100.0% | 0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.